Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-04-07
2009-10-20
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S359100
Reexamination Certificate
active
07605175
ABSTRACT:
The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.
REFERENCES:
patent: 2989538 (1961-06-01), Flores et al.
patent: 3211731 (1965-10-01), Schmidt et al.
patent: 3211732 (1965-10-01), Schmidt et al.
patent: 5593356 (1997-01-01), Takeda
patent: 5593997 (1997-01-01), Dow et al.
patent: 6291504 (2001-09-01), Nugiel et al.
patent: 6407103 (2002-06-01), Nugiel et al.
patent: 6413957 (2002-07-01), Nugiel et al.
patent: 6531477 (2003-03-01), Markwalder et al.
patent: 6753329 (2004-06-01), Bockovich et al.
patent: 2001/0027195 (2001-10-01), Nugiel et al.
patent: 2003/0165873 (2003-09-01), Come et al.
patent: 2004/0043388 (2004-03-01), Come et al.
patent: 0203679 (1986-12-01), None
patent: 60-130521 (1985-07-01), None
patent: 62-099361 (1987-05-01), None
patent: WO 94/13677 (1994-06-01), None
patent: WO 98/05335 (1998-02-01), None
patent: WO 99/54308 (1999-10-01), None
patent: WO 00/21926 (2000-04-01), None
patent: WO 02/34721 (2002-05-01), None
patent: WO 02/40182 (2002-05-01), None
patent: WO 02/44174 (2002-06-01), None
patent: WO 02/067654 (2002-09-01), None
patent: WO 02/070662 (2002-09-01), None
patent: WO 02/093269 (2002-11-01), None
patent: WO 03/004491 (2003-01-01), None
patent: WO 03/033499 (2003-04-01), None
patent: WO 03/063764 (2003-08-01), None
Mosher, at al; “Benzene Ring Substituted Indeno[1,2-c]pyrazol-4(1H)-ones”; J. Org. Chem, vol. 35, No. 11, 1970 pp. 3685-3688.
Nugiel, et al; “Indenopyrazoles as Novel Cyclin Dependent Kinase (CDK) Inhibitors”; J Med Chem. 2001, 44, 1334-1336.
Nugiel, et al; “Synthesis and Evaluation of lndenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 2. Probing the Indeno Ring Substituent Pattern”; J Med Chem, 2002, 45, 5524-5232.
Yue, et al; “Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 3. Structure Activity Relationships at C3 (1,2)”; J Med Chem 2002, 45, 5233-5248.
Shaw, et al., “Purines, pyimidines and Imidazoles . . . ”; Chemical Abstracts, vol. 75 No. 1; Jul. 5, 1971, Columbus, Ohio, abstract No. 5837.
“Protein Kinase Targets: Strategies for Drug Development”; Conference presentation Jun. 10-11, 2003; Westin Copley Place Hotel, Boston, MA.
Search Report from International Application No. PCT/US2004/010381 dated Feb. 3, 2005.
Becker Frank
Bockovich Nicholas
Come Jon H.
Kluge Arthur F.
Murthi Krishna K.
GPC Biotech AG
GPC Biotech Inc.
Saeed Kamal A
Wesolowski Michael R.
Yankwich Leon R.
LandOfFree
Inhibitors of cyclin-dependent kinases, compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of cyclin-dependent kinases, compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of cyclin-dependent kinases, compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4126013